Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Has Average Target Price of $38.00 According to Brokerages

Posted by Francis Steltz on Oct 28th, 2026

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have been given an average recommendation of “Moderate Buy” by the eleven research firms that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $38.00.

ARQT has been the topic of a number of research analyst reports. Cantor Fitzgerald assumed coverage on shares of Arcutis Biotherapeutics in a research note on Thursday, October 15th. They issued an “overweight” rating and a $48.00 price target on the stock. Guggenheim upped their price objective on shares of Arcutis Biotherapeutics from $38.00 to $44.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. Jefferies Financial Group reiterated a “buy” rating and set a $39.00 price objective on shares of Arcutis Biotherapeutics in a research report on Thursday, October 8th. Wall Street Zen downgraded shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 10th. Finally, Morgan Stanley raised their target price on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th.

Read Our Latest Research Report on ARQT

Insider Activity at Arcutis Biotherapeutics

In other news, insider Todd Watanabe sold 4,375 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $114,275.00. Following the completion of the transaction, the insider directly owned 717,203 shares in the company, valued at approximately $18,733,342.36. This represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Howard Welgus sold 4,730 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $26.18, for a total value of $123,831.40. Following the completion of the transaction, the director owned 36,475 shares of the company’s stock, valued at $954,915.50. The trade was a 11.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 83,953 shares of company stock valued at $2,143,291. 9.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Arcutis Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Montanova Capital LLC raised its position in Arcutis Biotherapeutics by 0.9% in the second quarter. Montanova Capital LLC now owns 12,437,000 shares of the company’s stock valued at $326,098,000 after purchasing an additional 110,000 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Arcutis Biotherapeutics during the second quarter worth about $276,502,000. Bank of America Corp DE bought a new stake in shares of Arcutis Biotherapeutics during the second quarter worth about $78,330,000. Janus Henderson Group PLC grew its holdings in shares of Arcutis Biotherapeutics by 1.3% during the first quarter. Janus Henderson Group PLC now owns 1,854,566 shares of the company’s stock worth $43,684,000 after purchasing an additional 24,505 shares during the last quarter. Finally, Jupiter Topco LLC bought a new stake in shares of Arcutis Biotherapeutics during the second quarter worth about $36,989,000.

Arcutis Biotherapeutics Stock Down 0.4%

NASDAQ:ARQT opened at $31.68 on Wednesday. The stock’s 50-day simple moving average is $26.32 and its 200 day simple moving average is $25.22. Arcutis Biotherapeutics has a twelve month low of $19.30 and a twelve month high of $33.30.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.05. The business had revenue of $129.86 million during the quarter, compared to the consensus estimate of $118.85 million. As a group, sell-side analysts predict that Arcutis Biotherapeutics will post 0.43 EPS for the current year.

Arcutis Biotherapeutics Company Profile

(Get Free Report)

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.